I'm sure your competent? doctor and hospital have already selected the best tDCS recovery option out there! Oh no, they know nothing and have DONE NOTHING! Well, they're getting paid regardless of their incompetency! Just be quiet about it and let them think they are getting away with it. Schadenfreude will be a complete bitch for them when they become the 1 in 4 per WHO that has a stroke.
anodal tDCS (26 posts to August 2015)
HD-tDCS (8 posts to January 2013)
cathodal tDCS (21 posts to July 2013)
tDCS (95 posts to April 2011)
Bicephalic tDCS (1 post to June 2022)
c-tDCS (3 posts to September 2019)
Dual-tDCS (1 post to January 2014)
remote tDCS (1 post to August 2022)
RS-tDCS (1 post to August 2022)
But did you invalidate this research?
Transcranial Brain Stimulation: No Benefit for Stroke Rehab September 2021
The latest here:
Neurophet wins Samsung Medical Center as 1st customer for its AI stroke rehab device
Neurophet has landed its first tertiary hospital client in Korea for its AI-guided brain stimulation platform, supplying a personalized transcranial direct current stimulation (tDCS) solution to Samsung Medical Center (SMC) as it looks to turn an “innovative medical technology” label into real-world business.
Neurophet headquarters in Gangnam-gu, Seoul. (Credit: Neurophet)
The Kosdaq-listed company, which focuses on AI for brain disease diagnosis and treatment, said Thursday that SMC has introduced Neurophet’s personalized tDCS package, combining its Neurophet tES LAB planning software with “Neurophet innk,” a transcranial electrical stimulation device.
The setup is designed to help restore finger motor function in patients with stroke-induced paralysis when used alongside standard rehabilitation therapy.
The deal is the first time Neurophet’s personalized tDCS solution, designated earlier this year as an innovative medical technology in Korea, has been installed at a top-tier referral center. Neurophet said it is positioning the SMC deployment as a reference site as it pitches the system to other hospitals.
Using a patient’s brain MRI, Neurophet tES LAB maps and calculates the optimal stimulation target and parameters tailored to the individual. Neurophet innk then delivers non-invasive electrical stimulation to those brain regions, with the goal of improving fine motor recovery in affected fingers.
Under Korea’s innovative medical technology program, technologies that clear safety and potential-benefit thresholds can be used in clinical practice for a defined period while real-world data accumulate ahead of reimbursement decisions.
Neurophet’s personalized tDCS solution can be used in clinical care through June 30, 2028, after which hospitals may be able to bill it as a reimbursed or non-reimbursed service depending on how coverage is set.
“It is an encouraging achievement that discussions with SMC so quickly led to a supply contract for our tDCS solution,” Neurophe Co-CEO Jake Been said in a statement. “Based on this, we plan to actively expand deployment across medical institutions in Korea.”
출처 : KBR(https://www.koreabiomed.com)
Neurophet headquarters in Gangnam-gu, Seoul. (Credit: Neurophet)
The Kosdaq-listed company, which focuses on AI for brain disease diagnosis and treatment, said Thursday that SMC has introduced Neurophet’s personalized tDCS package, combining its Neurophet tES LAB planning software with “Neurophet innk,” a transcranial electrical stimulation device.
The setup is designed to help restore finger motor function in patients with stroke-induced paralysis when used alongside standard rehabilitation therapy.
The deal is the first time Neurophet’s personalized tDCS solution, designated earlier this year as an innovative medical technology in Korea, has been installed at a top-tier referral center. Neurophet said it is positioning the SMC deployment as a reference site as it pitches the system to other hospitals.
Using a patient’s brain MRI, Neurophet tES LAB maps and calculates the optimal stimulation target and parameters tailored to the individual. Neurophet innk then delivers non-invasive electrical stimulation to those brain regions, with the goal of improving fine motor recovery in affected fingers.
Under Korea’s innovative medical technology program, technologies that clear safety and potential-benefit thresholds can be used in clinical practice for a defined period while real-world data accumulate ahead of reimbursement decisions.
Neurophet’s personalized tDCS solution can be used in clinical care through June 30, 2028, after which hospitals may be able to bill it as a reimbursed or non-reimbursed service depending on how coverage is set.
“It is an encouraging achievement that discussions with SMC so quickly led to a supply contract for our tDCS solution,” Neurophe Co-CEO Jake Been said in a statement. “Based on this, we plan to actively expand deployment across medical institutions in Korea.”
출처 : KBR(https://www.koreabiomed.com)
No comments:
Post a Comment